M
Malcolm K. Brenner
Researcher at Center for Cell and Gene Therapy
Publications - 632
Citations - 50064
Malcolm K. Brenner is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 109, co-authored 606 publications receiving 45233 citations. Previous affiliations of Malcolm K. Brenner include St. Jude Children's Research Hospital & Northwick Park Hospital.
Papers
More filters
Journal ArticleDOI
Rapid expression of protooncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore
TL;DR: Results document that expression of c-fos and c-myc genes, which are among the earliest events following stimulation of the protein kinase signal transduction pathway, can be successfully induced in B-CLL cells, and provide further evidence for the hypothesis that signal transmission downstream of protein Kinase C is intact in B -CLL.
Journal ArticleDOI
Vaccine therapies for pediatric malignancies.
TL;DR: Promising results in neuroblastoma and acute leukemia, suing genetically modified whole cell vaccines, peptides, and dendritic cells are described and a strategy for cancer vaccine development is outlined.
Journal ArticleDOI
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4+ T cells
Jan A. Rath,Gagan Bajwa,B.M. Carreres,Elisabeth Hoyer,Isabelle Gruber,Melisa Martinez-Paniagua,Yi-Ru Yu,Nazila Nouraee,Fatemeh Sadeghi,Meng-Fen Wu,Tao Wang,Michael Hebeisen,Nathalie Rufer,Navin Varadarajan,Ping-Chih Ho,Malcolm K. Brenner,David Gfeller,Caroline Arber,Caroline Arber,Caroline Arber +19 more
TL;DR: This study identifies molecular features of TCR8 expression that can guide the development of enhanced immunotherapies and found sustained activation of cytotoxicity, costimulation, oxidative phosphorylation– and proliferation-related genes, and simultaneously reduced differentiation and exhaustion.
Journal ArticleDOI
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
Mary K. McKenna,Alexander Englisch,Alexander Englisch,Benjamin Brenner,Benjamin Brenner,Tyler Smith,Valentina Hoyos,Masataka Suzuki,Malcolm K. Brenner +8 more
TL;DR: In this paper, mesenchymal stromal cells (MSCs) are used to deliver a binary vector containing an engineered adenovirus (OAd) together with a helper-dependent Ad (HDAd; combinatorial Ad vector [CAd]) that expresses interleukin-12 (IL-12) and checkpoint PD-L1 (programmed death-ligand 1) blocker.
Journal ArticleDOI
Gene transfer into human hemopoietic progenitor cells.
TL;DR: This chapter describes how gene transfer is being used to modify the drug sensitivity of progenitor cells--enabling them to resist the suppressive effects of cytotoxic drugs during cancer therapy and perhaps providing a mechanism for in vivo selection of gene modified cells.